Facebook Pixel
Biotech 2050 Podcast

Transforming chemotherapy for better patient outcomes, Jack Bailey, CEO, G1 Therapeutics

Biotech 2050 Podcast
Biotech 2050 Podcast
Synopsis:
Jack Bailey is the CEO of G1 Therapeutics, a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. Jack worked at Eli Lilly for 19 years followed by GSK for 12 years, and served on the company board at G1 Therapeutics before stepping into the role of CEO. Jack provides his perspective on the state of the industry and how the current macro environment is affecting financing, the supply chain, and attracting and retaining talent. He talks about his team’s work at G1, the proactive approach they’re taking to combat cancer, and the unique commercial aspect of the company. He also discusses the current legislative and regulatory environment, concerns he has, and opportunities for the future.

Biography:
As Chief Executive Officer, Jack Bailey leads G1 in its mission to fundamentally change the chemotherapy experience for patients with cancer. Mr. Bailey has over thirty years of commercial pharmaceutical experience and has an in-depth understanding of the healthcare marketplace. He has extensive experience in commercialization, health systems, health policy, and government affairs.

Previously, Mr. Bailey led the GlaxoSmithKline pharmaceuticals and vaccines business as President of the U.S., with responsibility for commercialization efforts across the company—oncology, immunology/rare disease, respiratory, and vaccines portfolios. He also was a member of the company’s Pharmaceutical Investment Board responsible for the clinical development investments by the company. Earlier in his career, he held various senior commercial leadership positions at Eli Lilly and Company, including Senior Vice President of the Account-Based Markets Division that included both the oncology and cardiovascular portfolios along with the managed markets groups.

Mr. Bailey was appointed to the G1 Therapeutics Board of Directors in March 2020 and in September 2020, he was named CEO. He also serves on the board of the UNC Health System, Emergo Therapeutics, a privately-held biotechnology company, and is a past member of the board at Harvard T.H. Chan School of Public Health, the board of directors of PhRMA, the pharmaceutical industry trade association, and the North Carolina Biotechnology Center. He holds an MBA from the University of North Carolina and a B.S. in biology from Hobart College.
Biotech 2050 Podcast
Not playing